Cyabra CTO acquires stock and new warrants

Cyabra, Inc. Chief Technology Officer Shraga Ido purchased 53,650 shares of common stock from the company in a private placement at $0.435 per share, bringing his direct holdings to 894,199 shares.

Rhea-AI Filing Summary

Cyabra, Inc. Chief Technology Officer Shraga Ido purchased 53,650 shares of common stock from the company in a private placement at $0.435 per share, bringing his direct holdings to 894,199 shares.

He also acquired Series A and Series B warrants, each to purchase up to 53,650 common shares, with exercise prices of $0.45 and $0.50 per share. These warrants become exercisable only after requisite stockholder approval; the Series B warrants expire 12 months and the Series A warrants five years after their initial exercise dates.

Filing Explained

The CTO acquired 53,650 shares; up to 107,300 more are conditional warrant capacity awaiting stockholder approval.

A Form 4 reports an insider transaction within two business days; this filing records Cyabra's chief technology officer acquiring 53,650 common shares from the issuer on July 10, 2026, in a private placement at $0.435 per share.

The same filing records purchases of Series B warrants for up to 53,650 common shares at a $0.45 exercise price and Series A warrants for up to 53,650 common shares at a $0.50 exercise price. The 53,650 common shares are acquired in the reported transaction, while the up-to-107,300 warrant shares are only potential additional issuance because both series require stockholder approval before exercise.

A private placement is a sale of securities to selected investors outside a public offering; the filing identifies the CTO as a participant. Series B warrants expire 12 months after their initial exercise date, and Series A warrants expire five years after their initial exercise date.

After the reported transactions, the filing lists 894,199 directly held common shares, 53,650 Series B warrants, and 107,300 Series A warrants. The specific follow-up item is the requisite stockholder approval, which controls when either warrant series can become exercisable.

Insider Trade Summary

Net Buyer: 107,300 shares

Net Buy 3 txns

Insider Shraga Ido

Role Chief Technology Officer

Bought 107,300 shs ($51K)

Type	Security	Shares	Price	Value
Purchase	Common Stock Warrants (right to buy) F2, F3, F4	53,650	$0.45	$24K
Purchase	Common Stock Warrants (right to buy) F5, F6, F7	53,650	$0.50	$27K
Grant/Award	Common Stock F1	53,650	$0.00	$0.00

Holdings After Transaction: Common Stock Warrants (right to buy) — 160,950 contracts (Direct); Common Stock — 894,199 shares (Direct)

Footnotes (7)

1. F1. On July 10, 2026, the Reporting Person purchased 53,650 shares of common stock, par value $0.0001 per share (the "Common Stock"), from the Issuer in a private placement transaction (the "Private Placement") at a purchase price of $0.435 per share.
2. F2. The Reporting Person purchased Series B warrants to purchase up to 53,650 shares of Common Stock (the "Series B Warrants") in the Private Placement.
3. F3. The Series B Warrants will become exercisable upon the receipt of the requisite stockholder approval.
4. F4. The Series B Warrants expire on the date that is twelve (12) months following the initial exercise date.
5. F5. The Reporting Person purchased Series A warrants to purchase up to 53,650 shares of Common Stock (the "Series A Warrants") in the Private Placement.
6. F6. The Series A Warrants will become exercisable upon the receipt of the requisite stockholder approval.
7. F7. The Series A Warrants expire five (5) years following the initial exercise date.

Key Figures

Common shares purchased: 53,650 shares Purchase price per share: $0.435 Direct common shares after transaction: 894,199 shares +5 more

8 metrics

Common shares purchased 53,650 shares Purchased from Cyabra in a private placement on July 10, 2026 at $0.435 per share

Purchase price per share $0.435 Price paid for each common share in the private placement

Direct common shares after transaction 894,199 shares Direct holdings of Cyabra common stock following the July 10, 2026 purchase

Series A Warrants underlying shares 53,650 shares Number of common shares purchasable under the Series A Warrants acquired

Series A exercise price $0.45 per share Exercise price of the Series A Warrants for Cyabra common stock

Series B Warrants underlying shares 53,650 shares Number of common shares purchasable under the Series B Warrants acquired

Series B exercise price $0.50 per share Exercise price of the Series B Warrants for Cyabra common stock

Series B warrant term 12 months Series B Warrants expire 12 months after their initial exercise date

Key Terms

Private Placement, Series B Warrants, Series A Warrants, requisite stockholder approval, +1 more

5 terms

Private Placement financial

"purchased 53,650 shares of common stock ... in a private placement transaction"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

Series B Warrants financial

"purchased Series B warrants to purchase up to 53,650 shares of Common Stock"

Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.

Series A Warrants financial

"purchased Series A warrants to purchase up to 53,650 shares of Common Stock"

Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.

requisite stockholder approval regulatory

"will become exercisable upon the receipt of the requisite stockholder approval"

initial exercise date financial

"expire on the date that is twelve (12) months following the initial exercise date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CYAB’s CTO report on July 10, 2026?

Cyabra’s CTO Shraga Ido bought 53,650 common shares at $0.435 per share in a private placement, raising his direct holdings to 894,199 shares. He also acquired Series A and Series B warrants, each allowing purchase of up to 53,650 additional common shares.

How many CYAB shares does Shraga Ido hold after the reported transaction?

After the purchase, Shraga Ido directly holds 894,199 shares of Cyabra common stock. This reflects the addition of 53,650 shares acquired from the company in a private placement at $0.435 per share, as disclosed in the Form 4 filing.

What warrants did the CYAB CTO acquire and what shares do they cover?

Shraga Ido acquired Series A and Series B warrants, each to purchase up to 53,650 shares of Cyabra common stock. In total, the warrants cover potential purchases of two separate 53,650-share blocks, subject to their respective exercise terms and expirations.

At what prices can the CYAB warrants be exercised by the CTO?

The warrants reported by CYAB’s CTO have exercise prices of $0.45 per share for the Series A Warrants and $0.50 per share for the Series B Warrants. Each series relates to 53,650 underlying common shares, exercisable after stockholder approval.

When do the Series A and Series B CYAB warrants held by the CTO expire?

The Series B Warrants expire 12 months after their initial exercise date, while the Series A Warrants expire five years after their initial exercise date. Both series become exercisable only after Cyabra obtains the requisite stockholder approval.

Was the CYAB CTO’s share purchase an open-market buy or a private deal?

The CTO’s acquisition of 53,650 CYAB common shares was through a private placement with the company, at a price of $0.435 per share. The same private placement also included his purchases of Series A and Series B stock warrants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 05:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shraga Ido

(Last) (First) (Middle)

C/O CYABRA, INC.

13 GERSHON SHATZ

(Street)

TEL AVIV 6997543

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYABRA, INC. [ CYAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2026		A		53,650(1)	A	$0	894,199	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Warrants (right to buy)(2)	$0.45	07/10/2026		P		53,650		(3)	(4)	Common Stock	53,650	$0.45	53,650	D
Common Stock Warrants (right to buy)(5)	$0.5	07/10/2026		P		53,650		(6)	(7)	Common Stock	53,650	$0.5	107,300	D

Explanation of Responses:

1. On July 10, 2026, the Reporting Person purchased 53,650 shares of common stock, par value $0.0001 per share (the "Common Stock"), from the Issuer in a private placement transaction (the "Private Placement") at a purchase price of $0.435 per share.

2. The Reporting Person purchased Series B warrants to purchase up to 53,650 shares of Common Stock (the "Series B Warrants") in the Private Placement.

3. The Series B Warrants will become exercisable upon the receipt of the requisite stockholder approval.

4. The Series B Warrants expire on the date that is twelve (12) months following the initial exercise date.

5. The Reporting Person purchased Series A warrants to purchase up to 53,650 shares of Common Stock (the "Series A Warrants") in the Private Placement.

6. The Series A Warrants will become exercisable upon the receipt of the requisite stockholder approval.

7. The Series A Warrants expire five (5) years following the initial exercise date.

	/s/ Yael Sandler, Attorney-in-Fact	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)